Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease
脑脊液
医学
疾病
阿尔茨海默病
病理
作者
Michelle Safransky,Jenna Rae Groh,Kaj Blennow,Henrik Zetterberg,Yorghos Tripodis,Brett M. Martin,Jason L. Weller,Breton Michael Asken,Gil Dan Rabinovici,Wendy Wei Qiao Qiu,Ann Carolyn McKee,Thor D. Stein,Jesse Mez,Rachel L. Henson,Justin M. Long,John C. Morris,Richard J. Perrin,Suzanne E. Schindler,Michael Louis Alosco
出处
期刊:Neurology [Lippincott Williams & Wilkins] 日期:2024-11-04卷期号:103 (11): e209866-e209866被引量:10
BACKGROUND AND OBJECTIVES: CSF biomarkers of Aβ42 and phosphorylated tau (p-tau181) are used clinically for the detection of Alzheimer disease (AD) pathology during life. CSF biomarker validation studies have largely used clinical diagnoses and/or amyloid PET imaging as the reference standard. The few existing CSF-to-autopsy studies have been restricted to late-stage AD. This CSF-to-autopsy study investigated associations between CSF biomarkers of AD and AD neuropathologic changes among brain donors who had normal cognition at the time of lumbar puncture (LP). METHODS: , and interval between LP and death. RESULTS: = 0.005). Effects remained after controlling for prevalent comorbid neuropathologies. CSF p-tau181/Aβ42 was strongly associated with CERAD ratings of neuritic amyloid plaque scores and Braak staging of NFTs. DISCUSSION: This study supports Lumipulse-measured CSF Aβ42 and p-tau181 and, particularly, the ratio of p-tau181 to Aβ42, for the early detection of AD pathophysiologic processes. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that Lumipulse measures of p-tau181/Aβ42 in the CSF accurately discriminated cognitively normal participants with and without Alzheimer disease neuropathologic change.